New Fortress Energy
NFE
Hutchmed (China)
HCM
Halozyme Therapeutics
HALO
Workday
WDAY
Lantheus
LNTH
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow (Indirect Method) | ||||||||||
Cash flow from continuing operating activities | 40.79%155.03M | 37.22%52.07M | 43.44%45.09M | 59.95%36.42M | 19.42%21.46M | 33.55%110.12M | 27.73%37.95M | 31.90%31.43M | 15.80%22.77M | 94.27%17.97M |
Net income from continuing operations | 34.93%124.94M | 24.25%30.72M | 23.37%32.04M | 46.96%33.06M | 50.04%29.13M | 39.25%92.6M | 40.95%24.72M | 44.81%25.97M | 34.98%22.49M | 35.20%19.42M |
Operating gains losses | 54.73%-153K | -120.31%-141K | 117.31%9K | 88.11%-22K | 102.70%1K | 47.84%-338K | 87.45%-64K | 29.73%-52K | -485.42%-185K | 66.96%-37K |
Depreciation and amortization | 14.50%32.19M | 12.21%8.07M | 13.44%8.02M | 17.14%8.09M | 15.30%8.01M | 7.12%28.11M | 18.26%7.19M | 5.37%7.07M | 3.41%6.91M | 2.52%6.95M |
Deferred tax | -14.76%-11.07M | -19.73%-11.07M | --0 | --0 | --0 | -71.74%-9.65M | -63.90%-9.25M | -412.50%-25K | -832.00%-366K | 70.59%-10K |
Change In working capital | 150.98%2.95M | 62.23%22.91M | 228.81%3.71M | 12.56%-6.72M | -81.30%-16.95M | 19.20%-5.79M | 25.37%14.12M | -99.24%-2.88M | -65.90%-7.68M | 24.31%-9.35M |
-Change in receivables | 77.26%-1.44M | 52.07%8.37M | 350.43%13.4M | -4,233.24%-14.05M | -33.92%-9.16M | 43.94%-6.35M | -26.93%5.5M | 21.66%-5.35M | -29.31%340K | 45.30%-6.84M |
-Change in inventory | 131.79%10.32M | 382.85%13.69M | 200.36%3.89M | 93.09%-851K | 44.01%-6.41M | -54.45%-32.47M | -0.52%-4.84M | -21.74%-3.88M | -32.97%-12.31M | -203.99%-11.44M |
-Change in prepaid assets | -118.37%-15.31M | -2,923.97%-7.54M | 131.19%717K | 85.11%-424K | -278.11%-8.07M | 33.58%-7.01M | 123.18%267K | -83.63%-2.3M | 45.76%-2.85M | 26.55%-2.13M |
-Change in payables and accrued expense | -242.97%-12.16M | -83.24%-6.92M | -544.73%-18.58M | 369.78%5.38M | 14.38%7.96M | -69.63%8.51M | -191.27%-3.78M | 11.65%4.18M | -87.79%1.15M | -35.26%6.96M |
-Change in other current liabilities | -31.66%21.55M | -9.75%15.31M | -4.12%4.28M | -46.07%3.23M | -131.16%-1.28M | 307.82%31.53M | 205.09%16.97M | -26.52%4.47M | 29,875.00%6M | 204.51%4.11M |
Cash from discontinued investing activities | ||||||||||
Operating cash flow | 40.79%155.03M | 37.22%52.07M | 43.44%45.09M | 59.95%36.42M | 19.42%21.46M | 33.55%110.12M | 27.73%37.95M | 31.90%31.43M | 15.80%22.77M | 94.27%17.97M |
Investing cash flow | ||||||||||
Cash flow from continuing investing activities | 45.70%-15.82M | -127.31%-4.67M | -3.92%-3.13M | 14.53%-2.34M | 73.38%-5.68M | -394.48%-29.13M | -71.02%-2.05M | -57.22%-3.01M | -67.83%-2.74M | -1,768.80%-21.32M |
Net PPE purchase and sale | -6.79%-12.82M | -127.31%-4.67M | -3.92%-3.13M | 12.12%-2.34M | 37.34%-2.68M | -103.75%-12M | -71.02%-2.05M | -57.22%-3.01M | -63.24%-2.66M | -274.32%-4.27M |
Net business purchase and sale | 82.48%-3M | --0 | --0 | --0 | 82.41%-3M | ---17.13M | --0 | --0 | ---75K | ---17.05M |
Cash from discontinued investing activities | ||||||||||
Investing cash flow | 45.70%-15.82M | -127.31%-4.67M | -3.92%-3.13M | 14.53%-2.34M | 73.38%-5.68M | -394.48%-29.13M | -71.02%-2.05M | -57.22%-3.01M | -67.83%-2.74M | -1,768.80%-21.32M |
Financing cash flow | ||||||||||
Cash flow from continuing financing activities | -24.96%-35.1M | -26.11%-9.99M | -42.49%-9.99M | -12.47%-7.41M | -17.42%-7.71M | -14.14%-28.09M | -33.14%-7.92M | -7.50%-7.01M | -5.12%-6.59M | -11.91%-6.57M |
Net common stock issuance | --0 | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- |
Cash dividends paid | -23.39%-35.85M | -26.11%-9.99M | -26.13%-9.99M | -20.38%-7.93M | -19.86%-7.94M | -16.76%-29.05M | -20.17%-7.92M | -20.32%-7.92M | -12.80%-6.59M | -12.90%-6.63M |
Proceeds from stock option exercised by employees | -22.34%751K | --0 | --0 | --521K | 296.55%230K | 37.55%967K | --0 | 1,390.16%909K | --0 | --58K |
Cash from discontinued financing activities | ||||||||||
Financing cash flow | -24.96%-35.1M | -26.11%-9.99M | -42.49%-9.99M | -12.47%-7.41M | -17.42%-7.71M | -14.14%-28.09M | -33.14%-7.92M | -7.50%-7.01M | -5.12%-6.59M | -11.91%-6.57M |
Net cash flow | ||||||||||
Beginning cash position | 38.92%191.78M | 58.96%258.96M | 59.52%226.21M | 55.27%199.31M | 38.92%191.78M | 58.36%138.05M | 41.92%162.91M | 41.51%141.81M | 43.87%128.36M | 58.36%138.05M |
Current changes in cash | 96.82%104.12M | 33.75%37.41M | 49.32%31.97M | 98.42%26.67M | 181.36%8.07M | 1.82%52.9M | 23.99%27.97M | 39.08%21.41M | 14.28%13.44M | -542.90%-9.92M |
Effect of exchange rate changes | -172.10%-597K | -218.24%-1.06M | 352.61%773K | 4,640.00%237K | -336.52%-544K | 176.88%828K | 27.52%899K | 62.59%-306K | 100.65%5K | 217.95%230K |
End cash Position | 53.98%295.31M | 53.98%295.31M | 58.96%258.96M | 59.52%226.21M | 55.27%199.31M | 38.92%191.78M | 38.92%191.78M | 41.92%162.91M | 41.51%141.81M | 43.87%128.36M |
Free cash flow | 44.95%142.22M | 32.06%47.4M | 47.63%41.96M | 69.50%34.08M | 37.12%18.78M | 28.15%98.11M | 25.90%35.89M | 29.68%28.42M | 11.51%20.11M | 68.94%13.7M |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |